Sanofi
1 year ago ⋅ English ⋅ 4 min read
Newsroom
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment

Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment- Transaction brings Qunol®, a trusted, profitable double-digit growth and market-leading brand in health... Read More
Sanofi
1 year ago ⋅ English ⋅ 2 min read
Newsroom
Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised

Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raisedQ2 2023 sales growth of 3.3% at CER and business EPS(1) growth of 8.1% at CER- Specialty Ca... Read More
Sanofi
1 year ago ⋅ English ⋅ 5 min read
Newsroom
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease- Beyfortus™ is the first monoclonal antibody approved to protect all infants through their first RSV sea... Read More
Sanofi
2 years ago ⋅ English ⋅ 5 min read
Newsroom
Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease- Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an... Read More
Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody- Amlitelimab sh... Read More
Sanofi
2 years ago ⋅ English ⋅ 7 min read
Newsroom
ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing- XTEND-Kids data confirm the efficacy... Read More